Sec Form 4 Filing - NEWMAN MARY @ Audentes Therapeutics, Inc. - 2018-03-15

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
NEWMAN MARY
2. Issuer Name and Ticker or Trading Symbol
Audentes Therapeutics, Inc. [ BOLD]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
SVP, Regulatory Affairs
(Last) (First) (Middle)
C/O AUDENTES THERAPEUTICS, INC., 600 CALIFORNIA STREET, 17TH FLOOR
3. Date of Earliest Transaction (MM/DD/YY)
03/15/2018
(Street)
SAN FRANCISCO, CA94108
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/15/2018 M( 1 ) 4,076 A $ 2.19 4,076 D
Common Stock 03/15/2018 S( 1 ) 4,076 D $ 29.6603 ( 2 ) 0 D
Common Stock 03/15/2018 M( 1 ) 5,524 A $ 2.19 5,524 D
Common Stock 03/15/2018 S( 1 ) 5,524 D $ 30.7902 ( 3 ) 0 D
Common Stock 03/15/2018 M( 1 ) 400 A $ 2.19 400 D
Common Stock 03/15/2018 S( 1 ) 400 D $ 31.617 ( 4 ) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $ 2.19 03/15/2018 M( 1 ) 10,000 ( 5 ) 02/04/2025 Common Stock 10,000 $ 0 23,817 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
NEWMAN MARY
C/O AUDENTES THERAPEUTICS, INC.
600 CALIFORNIA STREET, 17TH FLOOR
SAN FRANCISCO, CA94108
SVP, Regulatory Affairs
Signatures
/s/ Thomas Soloway as attorney-in-fact for Mary Newman 04/02/2018
Signature of Reporting Person Date
Explanation of Responses:
( 1 )This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
( 2 )Represents the weighted average sale price. The lowest price at which shares were sold was $29.25 and the highest price at which shares were sold was $30.24. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4 to this Form 4.
( 3 )Represents the weighted average sale price. The lowest price at which shares were sold was $30.27 and the highest price at which shares were sold was $31.20.
( 4 )Represents the weighted average sale price. The lowest price at which shares were sold was $31.50 and the highest price at which shares were sold was $31.66.
( 5 )The option vested as to 25% of the total shares on October 1, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on October 1, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.